Biogen Terminates Phase 4 Trial for Aducanumab, Transfers Ownership Rights

Biogen, the pharmaceutical company behind the development of aducanumab, has announced the termination of the Phase 4 trial mandated by the FDA for the drug. Aducanumab, a monoclonal antibody targeting beta-amyloid, had received accelerated approval in 2021. However, the company…